Dr. Colby Suire serves as Vice President of Research & Development at CNSide Diagnostics and Plus Therapeutics, where he leads scientific strategy and execution to advance the CNSide™ platform and strengthen the Company’s translational and diagnostic capabilities. Colby is responsible for expanding CNSide’s assay portfolio across high-value oncology indications, including implementation of FISH and next-generation sequencing technologies, and driving analytical validation, and operational scale-up through automation in CLIA-regulated environments.
Dr. Suire brings more than 18 years of experience in translational science and drug development, with a proven track record of advancing programs from discovery through clinical development and enabling regulatory milestones. His expertise spans preclinical pharmacology, biomarker strategy, and assay development, with direct contributions to IND-enabling programs and clinical-stage assets across oncology, immunology, and cell and gene therapy.
Prior to joining Plus Therapeutics, Dr. Suire served as CEO and Head of Development at K2 Biolabs, where he scaled translational services and expanded revenue-generating capabilities, and held senior leadership roles at Talaris Therapeutics and Neurogene. He has consistently built high-performing teams, established strategic partnerships, and accelerated development timelines to enhance program value and capital efficiency.
Dr. Suire earned his Ph.D. in Biomedical Science from The University of Texas Health Science Center at Houston and holds a B.S. in Biological Sciences from Louisiana State University.